{
    "data": [
        {
            "id": "1079801",
            "type": "article",
            "attributes": {
                "publishOn": "2012-12-24T04:15:04-05:00",
                "isLockedPro": false,
                "commentCount": 12,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Dividend Stock Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21835",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1079801-abbott-laboratories-dividend-stock-analysis"
            }
        },
        {
            "id": "1078401",
            "type": "article",
            "attributes": {
                "publishOn": "2012-12-21T18:28:41-05:00",
                "isLockedPro": false,
                "commentCount": 28,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Quality Dividend Aristocrat For Long-Term Dividends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21544",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1078401-abbott-laboratories-quality-dividend-aristocrat-for-long-term-dividends"
            }
        },
        {
            "id": "1028391",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-26T11:55:15-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Final Look At Combined Abbott Before The Split",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "108648",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1028391-a-final-look-at-combined-abbott-before-the-split"
            }
        },
        {
            "id": "1024011",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-21T16:09:07-05:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Abbott Laboratories In The Near Future",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "33161",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "108567",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1024011-buy-abbott-laboratories-in-the-near-future"
            }
        },
        {
            "id": "1021511",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-20T15:22:32-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Abbott Labs Reaches $67 Fair Value",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "108513",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/1021511-how-abbott-labs-reaches-67-fair-value"
            }
        },
        {
            "id": "991671",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-08T15:29:02-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: A Lucrative Play On Strong Revenue Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25159",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "108075",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/991671-abbott-a-lucrative-play-on-strong-revenue-growth"
            }
        },
        {
            "id": "990711",
            "type": "article",
            "attributes": {
                "publishOn": "2012-11-08T12:28:07-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Waiting To Buy This Healthcare Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "35521",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/990711-abbott-waiting-to-buy-this-healthcare-stock"
            }
        },
        {
            "id": "956221",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-26T18:37:41-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Cash In On This Big Pharma's Recent Pullback Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29161",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "107631",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/956221-abbott-cash-in-on-this-big-pharmas-recent-pullback-now"
            }
        },
        {
            "id": "951841",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-25T17:05:33-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How Big A Dividend Will Abbott Pay After It Splits?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/951841-how-big-a-dividend-will-abbott-pay-after-it-splits"
            }
        },
        {
            "id": "948861",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-25T05:36:12-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: A 'Must Buy' Pharma For Long-Term Gains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29021",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/948861-abbott-a-must-buy-pharma-for-long-term-gains"
            }
        },
        {
            "id": "943661",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-23T18:35:35-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: An Extra 31% With This Low Risk Technique",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22251",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/943661-abbott-laboratories-an-extra-31-percent-with-this-low-risk-technique"
            }
        },
        {
            "id": "938021",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-22T06:08:39-04:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories - Company Spin-Off Could Unlock Value For Shareholders",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/938021-abbott-laboratories-company-spin-off-could-unlock-value-for-shareholders"
            }
        },
        {
            "id": "933991",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-18T18:15:31-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "4 Reasons To Buy Abbott Shares On The Recent Pullback",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24627",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "107327",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/933991-4-reasons-to-buy-abbott-shares-on-the-recent-pullback"
            }
        },
        {
            "id": "933631",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-18T16:28:53-04:00",
                "isLockedPro": false,
                "commentCount": 25,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: No Capital Appreciation For The Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29461",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/933631-abbott-laboratories-no-capital-appreciation-for-the-stock"
            }
        },
        {
            "id": "927571",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-16T15:12:13-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Q3 Earnings Preview: What We're Watching",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23479",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/927571-abbott-q3-earnings-preview-what-were-watching"
            }
        },
        {
            "id": "926201",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-16T06:37:06-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Another Reason To Be Long AbbVie When Abbott Splits In Two",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "107174",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/926201-another-reason-to-be-long-abbvie-when-abbott-splits-in-two"
            }
        },
        {
            "id": "918531",
            "type": "article",
            "attributes": {
                "publishOn": "2012-10-11T11:29:28-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Holding Steady For Long-Term Investments",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25651",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "107012",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/918531-abbott-holding-steady-for-long-term-investments"
            }
        },
        {
            "id": "890191",
            "type": "article",
            "attributes": {
                "publishOn": "2012-09-26T14:27:28-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: A Second Stream Of Income In Addition To The Dividend",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22251",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/890191-abbott-laboratories-a-second-stream-of-income-in-addition-to-the-dividend"
            }
        },
        {
            "id": "885821",
            "type": "article",
            "attributes": {
                "publishOn": "2012-09-24T17:10:10-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Will Abbott's Magic Pill Send Stock Soaring?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29021",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/885821-will-abbotts-magic-pill-send-stock-soaring"
            }
        },
        {
            "id": "876981",
            "type": "article",
            "attributes": {
                "publishOn": "2012-09-19T17:08:35-04:00",
                "isLockedPro": false,
                "commentCount": 31,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Is Now A Sell",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21873",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "222203",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/876981-abbott-labs-is-now-a-sell"
            }
        },
        {
            "id": "858791",
            "type": "article",
            "attributes": {
                "publishOn": "2012-09-11T04:06:23-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Buy This Stock And Ride It Higher",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29021",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/858791-abbott-buy-this-stock-and-ride-it-higher"
            }
        },
        {
            "id": "849791",
            "type": "article",
            "attributes": {
                "publishOn": "2012-09-06T08:58:56-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott's Humira: A Drug To Buy Into",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "30861",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/849791-abbotts-humira-a-drug-to-buy-into"
            }
        },
        {
            "id": "846001",
            "type": "article",
            "attributes": {
                "publishOn": "2012-09-04T18:19:50-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "New Reasons To Be Bullish On Abbott Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25159",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/846001-new-reasons-to-be-bullish-on-abbott-now"
            }
        },
        {
            "id": "817391",
            "type": "article",
            "attributes": {
                "publishOn": "2012-08-20T11:54:19-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Is Overvalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25210",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/817391-abbott-labs-is-overvalued"
            }
        },
        {
            "id": "805841",
            "type": "article",
            "attributes": {
                "publishOn": "2012-08-14T12:13:25-04:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Reasons To Own AbbVie After Abbott Splits In Two",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23407",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "104822",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/805841-reasons-to-own-abbvie-after-abbott-splits-in-two"
            }
        },
        {
            "id": "805421",
            "type": "article",
            "attributes": {
                "publishOn": "2012-08-14T09:37:02-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: 4 Big Reasons To Buy Today",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25901",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/805421-abbott-laboratories-4-big-reasons-to-buy-today"
            }
        },
        {
            "id": "764311",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-31T06:26:57-04:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "M-M Theory Suggests Abbott As A Long-Term Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24389",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "104322",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/764311-m-m-theory-suggests-abbott-as-a-long-term-buy"
            }
        },
        {
            "id": "763411",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-30T18:18:13-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "New Study Deals Another Blow To Abbott Labs",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32821",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/763411-new-study-deals-another-blow-to-abbott-labs"
            }
        },
        {
            "id": "732881",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-19T12:58:19-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "While Not Expensive, Both Halves Of Abbott Need Work",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/732881-while-not-expensive-both-halves-of-abbott-need-work"
            }
        },
        {
            "id": "726461",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-17T12:41:51-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Earnings Preview: Abbott",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21445",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/726461-earnings-preview-abbott"
            }
        },
        {
            "id": "717761",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-12T12:51:41-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Earnings Preview: Abbott Laboratories",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29891",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/717761-earnings-preview-abbott-laboratories"
            }
        },
        {
            "id": "714051",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-11T07:03:05-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Undervalued Abbott Stock Despite Obamacare Taxes",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24866",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "103632",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/714051-buy-undervalued-abbott-stock-despite-obamacare-taxes"
            }
        },
        {
            "id": "712451",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-10T13:51:12-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories Is A Short",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "30201",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "221711",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/712451-abbott-laboratories-is-a-short"
            }
        },
        {
            "id": "701641",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-04T09:35:35-04:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Simple Dividend Stock Worksheet",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32571",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/701641-a-simple-dividend-stock-worksheet"
            }
        },
        {
            "id": "696151",
            "type": "article",
            "attributes": {
                "publishOn": "2012-07-02T08:24:27-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Will Jump On 3 Big Assets",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24114",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/696151-abbott-will-jump-on-3-big-assets"
            }
        },
        {
            "id": "673851",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-21T04:15:30-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott A Safe Bet In A Volatile Pharma Sector",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25901",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "102831",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/673851-abbott-a-safe-bet-in-a-volatile-pharma-sector"
            }
        },
        {
            "id": "666831",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-18T15:53:20-04:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories Dividend Stock Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21835",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/666831-abbott-laboratories-dividend-stock-analysis"
            }
        },
        {
            "id": "660981",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-14T21:48:34-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Beyond Humira",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25137",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "102575",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/660981-abbvie-beyond-humira"
            }
        },
        {
            "id": "659961",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-14T13:35:48-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Buy Ahead Of The Split",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25032",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "102554",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/659961-abbott-buy-ahead-of-the-split"
            }
        },
        {
            "id": "651181",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-11T14:13:53-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Avoid Abbott's $1.5 Billion Mess",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25953",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/651181-avoid-abbotts-1_5-billion-mess"
            }
        },
        {
            "id": "650271",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-11T09:23:31-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Trumps Peers In Dividend Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25319",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/650271-abbott-trumps-peers-in-dividend-growth"
            }
        },
        {
            "id": "644431",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-07T12:19:27-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Don't Sell This Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25159",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/644431-abbott-dont-sell-this-stock"
            }
        },
        {
            "id": "642201",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-06T17:55:06-04:00",
                "isLockedPro": false,
                "commentCount": 20,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Don't Worry About Abbott Labs' Dividend",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23704",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/642201-dont-worry-about-abbott-labs-dividend"
            }
        },
        {
            "id": "633691",
            "type": "article",
            "attributes": {
                "publishOn": "2012-06-04T01:30:07-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Get Paid, Avoid Market Volatility",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25901",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "102078",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/633691-abbott-get-paid-avoid-market-volatility"
            }
        },
        {
            "id": "624741",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-30T04:14:57-04:00",
                "isLockedPro": false,
                "commentCount": 11,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: A Closer Look At The Split",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "30861",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/624741-abbott-laboratories-a-closer-look-at-the-split"
            }
        },
        {
            "id": "621621",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-29T02:45:39-04:00",
                "isLockedPro": false,
                "commentCount": 116,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Have Abbott On A Stop-Loss Order",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22116",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/621621-why-i-have-abbott-on-a-stop-loss-order"
            }
        },
        {
            "id": "621471",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-29T02:26:51-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs: Learn From Grace Groner",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24610",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "101858",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/621471-abbott-labs-learn-from-grace-groner"
            }
        },
        {
            "id": "617901",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-25T09:13:22-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Don't Miss Out On Its High Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29021",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/617901-abbott-dont-miss-out-on-its-high-growth"
            }
        },
        {
            "id": "612221",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-23T12:35:31-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Abbott Is A Buy After The Lawsuit",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25651",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "101685",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/612221-why-abbott-is-a-buy-after-the-lawsuit"
            }
        },
        {
            "id": "602151",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-19T13:06:39-04:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Is Cheap, But AbbVie Will Likely Be Cheaper",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29611",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "101500",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/602151-abbott-is-cheap-but-abbvie-will-likely-be-cheaper"
            }
        },
        {
            "id": "570441",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-08T14:56:24-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bright Future Ahead Of Abbott Despite Mounting Competition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100996",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/570441-bright-future-ahead-of-abbott-despite-mounting-competition"
            }
        },
        {
            "id": "569401",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-08T11:32:13-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: New Reasons The Split Could Tank Stock",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25159",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "220138",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/569401-abbott-new-reasons-the-split-could-tank-stock"
            }
        },
        {
            "id": "550531",
            "type": "article",
            "attributes": {
                "publishOn": "2012-05-02T08:52:05-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs: A Big Pharma Offering Best ROI Growth",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24610",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100708",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/550531-abbott-labs-a-big-pharma-offering-best-roi-growth"
            }
        },
        {
            "id": "544061",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-30T19:23:57-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Long Opportunity: The Abbott Labs Split Strategy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23704",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100610",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/544061-long-opportunity-the-abbott-labs-split-strategy"
            }
        },
        {
            "id": "532591",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-26T15:35:51-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs - Split Will Unlock Nutritionals Business",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "28411",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100460",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/532591-abbott-labs-split-will-unlock-nutritionals-business"
            }
        },
        {
            "id": "532021",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-26T14:31:01-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott's 4.6% Quarterly Growth Will Boost Your Retirement Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25953",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100454",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/532021-abbotts-4_6-percent-quarterly-growth-will-boost-your-retirement-portfolio"
            }
        },
        {
            "id": "527171",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-25T13:02:12-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs Completely Overshadows Competitors",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "29491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "100394",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/527171-abbott-labs-completely-overshadows-competitors"
            }
        },
        {
            "id": "518461",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-23T12:49:15-04:00",
                "isLockedPro": false,
                "commentCount": 2,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Could Reach New Highs On Xience Prime",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25953",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/518461-abbott-could-reach-new-highs-on-xience-prime"
            }
        },
        {
            "id": "507921",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-18T15:38:39-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Which Half Of Abbott Is The Real Growth Story?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24361",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/507921-which-half-of-abbott-is-the-real-growth-story"
            }
        },
        {
            "id": "503381",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-17T11:26:13-04:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Earnings Preview: Abbott",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21445",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/503381-earnings-preview-abbott"
            }
        },
        {
            "id": "496421",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-13T12:05:49-04:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories Is Cheaper Than You Think",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21544",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/496421-abbott-laboratories-is-cheaper-than-you-think"
            }
        },
        {
            "id": "481751",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-05T15:59:50-04:00",
                "isLockedPro": false,
                "commentCount": 6,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Is A Solid Buy For Gains This Year",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25651",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "99565",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/481751-abbott-is-a-solid-buy-for-gains-this-year"
            }
        },
        {
            "id": "478921",
            "type": "article",
            "attributes": {
                "publishOn": "2012-04-04T13:11:30-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: A Strong Candidate For Growth In 2012",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24610",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/478921-abbott-a-strong-candidate-for-growth-in-2012"
            }
        },
        {
            "id": "465941",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-29T11:23:58-04:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott: Expect Strong Upside Movement, Both Pre And Post Research Division Spin-Off",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24610",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "99246",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/465941-abbott-expect-strong-upside-movement-both-pre-and-post-research-division-spin-off"
            }
        },
        {
            "id": "465021",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-29T05:27:20-04:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories Dividend Yield Beats The Treasury Bond Yield",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24492",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/465021-abbott-laboratories-dividend-yield-beats-the-treasury-bond-yield"
            }
        },
        {
            "id": "451581",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-22T12:43:54-04:00",
                "isLockedPro": false,
                "commentCount": 62,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Abbott Labs Is Only Good For Dividends",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25381",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/451581-why-abbott-labs-is-only-good-for-dividends"
            }
        },
        {
            "id": "429011",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-13T03:08:38-04:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Surging To $80, Shocking Naysayers",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24866",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98573",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/429011-abbott-surging-to-80-shocking-naysayers"
            }
        },
        {
            "id": "422261",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-09T04:26:33-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Taking The Pain Away For Rheumatoid Arthritis Patients",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "27151",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98467",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/422261-taking-the-pain-away-for-rheumatoid-arthritis-patients"
            }
        },
        {
            "id": "420251",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-08T11:01:12-05:00",
                "isLockedPro": false,
                "commentCount": 5,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Will Be A Winner This Year",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25159",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98443",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/420251-abbott-will-be-a-winner-this-year"
            }
        },
        {
            "id": "415691",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-06T16:59:00-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Anxiously Awaiting Abbott's Plans To Split Into Two",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "98362",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/415691-anxiously-awaiting-abbotts-plans-to-split-into-two"
            }
        },
        {
            "id": "411171",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-05T08:42:20-05:00",
                "isLockedPro": false,
                "commentCount": 1,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories' Share Price: Slightly Overvalued",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23209",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/411171-abbott-laboratories-share-price-slightly-overvalued"
            }
        },
        {
            "id": "404301",
            "type": "article",
            "attributes": {
                "publishOn": "2012-03-01T09:24:13-05:00",
                "isLockedPro": false,
                "commentCount": 3,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: Dividends, Earnings And Valuation Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25871",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/404301-abbott-laboratories-dividends-earnings-and-valuation-analysis"
            }
        },
        {
            "id": "394641",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-27T11:49:16-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Labs - Dividend Total Return Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24196",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/394641-abbott-labs-dividend-total-return-analysis"
            }
        },
        {
            "id": "374461",
            "type": "article",
            "attributes": {
                "publishOn": "2012-02-17T06:50:44-05:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: An Attractively Valued Dividend Aristocrat",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21544",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/374461-abbott-laboratories-an-attractively-valued-dividend-aristocrat"
            }
        },
        {
            "id": "321824",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-24T20:58:04-05:00",
                "isLockedPro": false,
                "commentCount": 0,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Earnings Preview: Abbott Laboratories",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21445",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/321824-earnings-preview-abbott-laboratories"
            }
        },
        {
            "id": "319761",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-16T03:39:55-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories: A Good Dividend Stock To Buy At $48-$52",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25275",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/319761-abbott-laboratories-a-good-dividend-stock-to-buy-at-48-52"
            }
        },
        {
            "id": "318815",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-11T08:48:03-05:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Against The Grain: Abbott Is Not Worth Your Money Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25159",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/318815-against-the-grain-abbott-is-not-worth-your-money-now"
            }
        },
        {
            "id": "317965",
            "type": "article",
            "attributes": {
                "publishOn": "2012-01-06T15:21:10-05:00",
                "isLockedPro": false,
                "commentCount": 7,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Abbott Laboratories Dividend Capture With Options",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22561",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1200",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/317965-abbott-laboratories-dividend-capture-with-options"
            }
        }
    ]
}